FDA oral Wegovy, solid fundamentals, and low P/E vs. Eli Lilly. Click for this updated look at NVO stock prospects as ...

Wegovy pill introduction in the U.S. may serve as the turning point that transforms a beleaguered GLP‑1 leader into a viable ...

The weight-loss war is moving from the needle to the medicine cabinet as Novo Nordisk ($NVO) officially launches its daily ...

Eli Lilly has the lead in the GLP-1 race, but Novo Nordisk just changed the game.

Novo Nordisk executive Dave Moore touted high interest in Wegovy's oral version of its injectable GLP-1 weight-loss ...

Novo Nordisk (NVO) downgraded to Hold after FDA GLP-1 actions and 2026 patent cliffs threaten Wegovy supply and growth. See ...

These two healthcare stocks are top names to invest in, but they haven't both been doing well of late. Eli Lilly has generated $25 billion in revenue from its fast-growing GLP-1 drugs this year. Novo ...

Eli Lilly & Co slashed the price of its blockbuster weight-loss and diabetes drug Mounjaro in China, intensifying competition ...

Novo Nordisk and Eli Lilly are significantly lowering prices of their blockbuster obesity drugs Wegovy and Mounjaro in China, ...

Novo Nordisk and Eli Lilly are reducing prices for their widely used obesity medications, Wegovy and Mounjaro, in China, a ...

Wegovy’s oral version of its injectable weight-loss drug is seeing tremendous interest, Novo Nordisk executive Dave Moore ...